WARNING: These elevator pitches are brief and concise by nature. By being so brief appropriate risks are not conveyed in these short statements. These elevator pitches reflect only the most positive optimistic personal opinions of the startup founders. Full risk statements are found at the bottom, in our private placement memorandum and other locations. These risk warnings include – Our patents may not hold up or protect us. Our patents pending may not be issued. We have too little data to support any performance claims definitively at this time. Early data is uncontrolled and is not statistically significant. We are underfunded for the work we plan to do. We are understaffed for the work we plan to do. Our small staff is diverted from focused attention with other jobs and many projects. All of our advisor, employment, supplier and patent license option agreements are subject to conditions which may not be met and are often in arrears due to financial constraints. We are attempting to achieve product performance goals never reached before by other groups with substantially higher amount of resources.

2018 Likely to Be In Position for Securing Strategic Partner

> OrthodontiCell = Competitor Invisilign is worth $13.7 billion. They straighten teeth in 18 months. We believe based on early small animal data and lab experiments and studies conducted with RANKL and OPG by others that we can straighten teeth in 6 months. They have no provision to freeze teeth straight > we believe we do with our patent pending bioelectric controlled release of OPG. Current Status = We are completing now final animal studies at Forysyth Institute in Boston and plan to enter clinical trials the 1st half of 2018 at Tufts University, UCLA and UCSF in San Francisco.

> VascuStim – Over 1 million diabetic related amputations are expected this year alone. Over 23 million amputations are expected by 2030. The diabetes population is exploding rising from 108 million in 1980 to 422 million in 2014 and expected to increase by 25 to 50% more by 2030. Vascustim through collaborations has completed clinical studies in Czech Republic, Germany, Switzerland and Mexico in more than 70 patients utilizing bioelectric microcurrent stimulation and/or stem cells. Over 30 papers have been published by a variety of teams from around the world documenting the benefits of bioelectric stimulation in improving wound healing A separate study was completed independently by researchers in Czech Republic demonstrating the benefit of adding selected growth factors. Our partners in Utah for amniotic fluid membranes have documented dozens of cases of diabetic leg and foot wound healing and numerous independent studies have been published documenting the same. The VascuStim approach is to combine specific bioelectric stimulation signals for stem cell homing, blood vessel growth, healing and tissue regeneration with stem cells and selected growth factors for healing diabetic foot and leg ulcers and for limb salvage. In some studies in some countries such as the USA we will utilize only bioelectric stimulation and amniotic fluid membranes to get started due to regulatory constraints. Our bench top bioelectric stimulator via our manufacturing partner in California already has FDA 510K market clearance for improving blood circulation. Amniotic fluid membranes are already marketed under the homologous exemption by our Utah based manufacturing partner. Current Status = We now are launching a worldwide paid registry clinical trial at more than 30 centers with plans for us getting paid for the product during the studies under category B designation reimbursement.

> Second Heart Assist = Competitor Abiomed is worth $8.4 billion. We believe we have designed a pump that has the potential to beat theirs in many performance parameters (Pending study data to confirm). Our 2nd generation chronic implant is on track to be first wireless powered device with long term protection against thrombosis and hemolysis. Current Status > We are completing now a series of large animal studies at leading U.S. institution (s) and plan to apply to the FDA to begin an Early Feasibility Study clinical trial some time in 2018. We have recruited an all-star team to lead this initiative including Dr. Leslie Miller as CMO, Jeff Donofrio as President, Dr. Mark Kroll as Senior Advisor, Dr. Mark Cunninham as Chief CardioThoracic Surgery Advisor, Dr. Samer Banihani as Chief Nephrology Advisor and Dr. Nic Chronos and Dr. Jon Sherman as Cardiology Advisors. Jane Reedy formerly from Thoratec and HeartWare has joined our team to lead Clinical and Regulatory Affairs with assistance from Larry Stevens, a former FDA reviewer, as our lead regulatory consultant and Todd Seiger as Chief Reimbursement Consultant. Product is in early stage testing. Any performance claims are subject to verification by properly controlled studies, which have yet to be completed.

> Stem Cell Bra = We believe our stem cell homing, proliferation and differentiation bioelectric bra can increase a woman’s breast fullness 30% in 4 to 6 weeks wearing the bra for only 1 hour every other day based on early stage sheep studies we completed in Argentina with these results. Over 1 billion women worldwide would be interested in acquiring a bra that increase their breast fullness safely by recruiting their own stem cells from their own fat and bone marrow with a homing signal. Current Status > We completed one round of successful sheep studies in Argentina with histopathology examination to verify safety. We are now are enrolling in second round of large animal studies. We recruited Dr. Joel Aronowitz of Cedars Sinai UCLA as Chief Medical Advisor. His team led the first ever case of stem cell repair of a cancer stricken breast in the USA with FDA clearance.

> HairCell = Competitor Samumed using WnT signaling technology is worth $12 billion. They get 10% hair growth. We believe we can achieve as high as 30% hair follicle density improvement. Current Status = We are planning to enter clinical trials in Canada and Argentina early 2018.

> CancerCell = Competitor Novocure reached $2 billion valuation this year. They use bioelectric signals to jam cancer tumor communication. Pulse Biosciences another competitor reached $450 million valuation peak this year. Both have published positive results utilizing bioelectric stimulation to shrink or eliminate cancer tumors, NovoCure in the brain and Pulse Biosciences for skin cancer. Pulse Biosciences changes the surface proteins of a tumor so the body attacks it – immunotherapy. Our CancerCell product has 7 part bioelectric therapy for cancer including early detection of tumors, reading tumors and custom jamming communication, cell division stop signal, blood supply starving signals, surface protein expression change so body attacks tumor – immunotherapy all followed by regeneration signals. Current Status = We have launched translational research studies at the Pacific Neurosciences Research Institute in Santa Monica, CA.

> BioLeonhardt = A Leonhardt team achieved 95.7 meters improvement in exercise capacity 6 minute walk testing over placebo in a Phase II/III trial of muscle stem cells alone in treating advanced heart failure at 33 leading sites the USA. We now are applying the combination of muscle stem cells with bioelectric stimulation, selected growth factors and other agents (exomsomes, Micro RNAs, heart matrix, nutrient hydrogel, selected alkaloids) with repeat delivery via a micro infusion pump. We have a goal with this new therapy combination to achieve 200 meters improvement in exercise capacity measure by 6 minute walk. CRT/ICD pacers are a $9 billion industry and they achieve only 16 to 20 meters improvement. We can program our patented and patent pending bioelectric stimulation signals for stem cell homing, proliferation and differentiation + 15+ regeneration and blood vessel growth promoting proteins into existing CRT/ICD pacers with an additional lead directed to the myocardial scar tissue. Our bioelectric programming includes real time monitoring and total management of inflammation via our InStim patent pending technology. This technology has the potential to be the first to totally regenerate failing hearts. Current status = we are completing animal studies at University of Utah and plan to enter clinical trials in late 2018 OUS.

2019 Likely to Be In Position for Securing Strategic Partner

> CerebraCell = Last year a Stanford team shocked the world reporting cerebral stroke patients in wheelchairs got up and walked again after one time injections of modified stem cells to the damaged brain regions. Our team working with the Pacific Neurosciences Institute in Santa Monica is embarking on translational research studies combining biolelectric stimulation controlled release of a stem cell homing protein with 14+ other brain regeneration promoting protein expression signals with a micro infusion pump and our CC-15 fifteen component brain regeneration composition comprised of stem cells, growth factors, amniotic fluid, selected alkaloids including harmine, exosomes, Micro RNAs, nutrient hyrdogel and brain matrix. Cerebracell has in its planned pipeline treatments not only for stroke but also for concussion, TBI, Alzheimer’s, Parkinson’s, Epilepsy and even for brain enhancement in healthy people with our Brain-N-Hance product. Current Status > Developing a non-invasive bioelectric stimulation helmet. Presented at Neuro Tech Leaders Forum and North Bay Innovation Summit. Launching translational research studies at Pacific Neurosciences Institute Santa Monica. Recruited Dr. Santosh Kesari as Chief Medical Advisor. Developing bridges to UCLA’s Brain Institute for collaborative research. Planning animal studies at Los Angeles Biomedical Institute and other locations. Consulting with experts at Tufts University. Recruited Dr. Warren Merrifield as an advisor with substantial brain diagnosis experience. Recruited Dr. Lin Nih from UCLA Brain Institute as an advisor. Working to file research grant applications. We just upgraded the web site www.cerebracell.com

> MyoStim ED – Over 322 million men worldwide suffer of erectile dysfunction. Our bioelectric stimulation method is comprised of a simple conductive wrap connected to either a bench top or miniature bioelectric stimulator. We believe our signals for expressing SDF-1, HGF, PDGF, VEGF, eNOS, HIF alpha, Follistatin and Tropoelastin will be more effective than other treatment options and less painful with less risk of infection the needle injections. Current Status – We recently applied for an NIH research grant working with Dr. Nestor Gonzalez-Cadavid at Los Angeles Biomedical Research Institute that is intended to lead through translational studies in collaboration with Harbor UCLA Medical Center.

> SkinCell Stimulator by MyoStim Skin – Well over 1 billion men and women worldwide use some product to attempt to improve the healthy youthful appearance of their facial and neck skin. Our bioelectric stimulation method is comprised of a simple conductive mask connected to either a bench top or miniature bioelectric stimulator. We believe our signals for expressing SDF-1, HGF, PDGF, VEGF, eNOS, HIF alpha, Follistatin and Tropoelastin will be more effective than other treatment options and less painful with less risk of infection the needle injections. Current Status – We are finalizing safety focused pre-clinical studies. We plan to launch an international clinical registry trial in multiple countries including Argentina, Canada, Mexico and Australia for skin regeneration.

> PancreaCell – Over 420 million worldwide suffer of diabetes. The primary cause of diabetes is a malfunctioning pancreas exasperated by chronic inflammation. Our PancreaCell product is designed to address both these underlying causes with a bioelectric treatment stand alone option in mild cases and for severe cases a combination bioelectric + micro infusion pump + fifteen component PC-15 pancreas regeneration composition with repeat deliveries. Current Status – We are in the process to apply to NIH, JDRF and other diabetes related research funding organizations in 2018 for grant funding working with the Diabetes Research Institute at the University of Miami with Dr. Camillo Ricordi. November of 2017 we made it to the finals of the nationwide American Diabetes Association National Innovation Pitch Contest. We recruited Dr. Harish Kapoor as President. Dr. Camillo Ricordi is aboard as advisor and we have reached out to engage research collaboration with Dr. Klearchos Papas at the University of Arizona.

> PressureStim – Over 1.2 billion people worldwide suffer of high blood pressure. Some estimates indicate up to 50% of all Americans suffer some form of blood pressure abnormality. High blood pressure increases the risk of many disease states that lead to premature death. Our team has developed a bioelectric stimulation modulation system designed to manage blood pressure in patients. Current Status – Patents filed. Searching for potential collaborative research partners in California and Utah.

> Valvublator – Our team patented and developed the first percutaneous heart valve which today is the standard of care for hundreds of thousands of patients. Today we believe we have obsoleted our own invention with an even better invention. The Valvublator helps people keep their own heart valve instead of getting an artificial or animal based implant. The current artificial heart valve market is nearly $9 billion annually. Cleaning, maintaining, regenerating your own heart valve is expected to open up a much larger market valued at over $15 billion annually. The concept is to clean up and regenerate heart valves early with a catheter based procedure before the disease is so progressed that malfunction occurs. We clean our teeth to stop plaque formation. We need to start doing the same with our heart valves. Our team is leading the way. Current Status – Patents filed. Working to build and testing first working prototypes. Set up to do first in man studies after pre-clinical studies in Italy with Dr. Antonio Colombo.

2020 Likely to Be In Position for Securing Strategic Partner

> LiverCell – About 50 million people worldwide suffer of liver disease. Our bioelectric stimulation + micro infusion pump + LC-15 fifteen component liver regeneration composition we believe can be more effective than other treatment options for liver function and health recovery. Current Status – We recruited Ben Boytor as President. We are working now to file research grant applications and have held some meetings with the liver regeneration team at Duke University to attempt to initiate translational research studies.

> BioPace – Over 3 million people worldwide have an implanted electronic pacemaker. The A-Fib market is estimated to be nearly $14 billion annually. Over 400,000 deaths annually in the USA alone are attributed to electrical heart abnormalities. All healthy people function well with a natural biological pacemaker made up of living cells and healthy conduction cells within their heart. BioPace is working to develop and has patent and patent pending a pipeline of products that utilize bioelectric signaling + stem cells + growth factors + optogenetics to restore normal pacing and electrical conduction within an ailing heart. We believe restoring your own natural heart pacing function with living cells, the way it is built in the first place, is a far better alternative to getting a steel can with an electronic circuit board, battery and steel leads in your heart. Current Status – Working with Dr. Alonso Moreno at the University of Utah Cardiovascular Research and Training Institute we are filing multiple research grant applications and we are building and testing prototypes as well as filing new patent claims.

> AortaCell – Our team in the 1990’s developed and patented one of the first and leading endovascular stent graft system for repairing aortic aneurysms without surgery. There are over $1 billion of annual sales of these products now worldwide. We now believe we have obsoleted our previous invention with AortaCell. AortaCell utilizes bioelectric stem cell homing, proliferation and differentiation signals to repair an aortic aneurysm with living cells and living smooth muscle instead of an artificial fabric and metal implant. Current Status – We have recruited Dr. Barry Katzen, Dr. Jacob Cynamon, Dr. Sam Ahn, Dr. Leslie Miller, Dr. Juan Parodi and Dr. Harrison Lazarus to the AortaCell team. They are leaders in the field of aortic aneurysm repair. We are currently building and testing prototypes and plan to begin pre-clinical animal studies soon.

> DentaCell Accelerator – Our team is leading an innovation accelerator focused on applying our core technology platform of bioelectric stimulation + micro infusion pumps + stem cell and growth factor based compositions to dentistry. We are combining this with a commitment to personalized, functional and holistic medicine approaches in dentistry. Current Status – We are developing products for controlling infections, inflammation, pain and accelerated healing related to dental procedures. We have recruited Tom Newman as President and Dr. Val Kanter as Chief Medical & Scientific Advisor. We expect to be initiating clinical trials soon. We have established tooth pulp banking services as our first commercial product.

> EyeCell – A number of reports have come out this year demonstrating the ability of stem cell injections to recover some forms of blindness. Some reports have highlighted the great risks associated with this type of research. We believe our product which comprises a combination of a bioelectric stimulator, which includes stem cell homing capability, a micro infusion pump and our EC-15 fifteen component eye regeneration composition can potentially be more effective and possibly safer than other treatment options. Current Status – We have completed two phases of pre-clinical studies of EyeCell in human cadaver eyes and we are now moving into animal studies at the University of Utah. We recently received animal ethics committee approval to begin the study.

2021 Likely to Be In Position for Securing Strategic Partner

> InStim – Noncommunicable chronic diseases such as inflammatory bowel diseases, cancer, diabetes, obesity, and pulmonary, cardiovascular, and neurodegenerative diseases are becoming the leading cause of death throughout the world. Most of these risk factors are closely linked to chronic inflammation, which leads to the development of these various chronic diseases. Over 2 billion people worldwide suffer of some form of inflammation. The market for anti-inflammatory drugs is expected to reach $106 billion by 2020. InStim is the first therapy designed and intended to read inflammation and custom delivers the precise bioelectric signals to express the precise correct anti-inflammatory or inflammatory cytokines in the proper sequence to promote optimal recovery, health and function. The InStim microprocessor holds information on the ideal healing responses in people that recover well from an event that may trigger inflammation. This is a baseline for custom bioelectric inflammation modulation. Current Status – Patents filed. Seeking out research partners to begin studies. Prototypes being built and tested.

> CoroStim VibroCell – Blood clot, calcification and plaque formation on blood contact surfaces is a leading cause of death. Thrombosis alone contributes to more than 52.8 million deaths annually according to the GBD. The CoroStim VibroCell team has developed a vibrational harmonic resonance energy technology that it believes can possibly stop blood clots, calcification and plaque from forming on both natural and artificial blood contact surfaces. Blood clots have been the Achille’s Heel of long term circulatory assist support devices and heart valves. Current Status – Patents filed. Building prototypes for testing. Seeking out research collaborators.

> KidneyCell – Over 2 million people worldwide receive treatment for chronic kidney disease or failure. 1 in 10 people in the USA will afflicted with kidney disease. Chronic kidney disease often triggers chronic inflammation which leads to multiple organ failure including heart failure. Our team has developed a combination bioelectric stimulator + micro infusion pump + KC-15 fifteen component kidney regeneration composition designed and intended for kidney regeneration and chronic inflammation treatment and management. We believe that this therapy can possibly be more effective than other treatment options. Current Status – Filed patents. Building and testing prototypes in our lab. Seeking research collaborators to initiate translational research studies.

> BladderCell – Nearly 300 million people worldwide suffer of some sort of bladder control problem. Our team has developed a combination bioelectric stimulator + micro infusion pump + BC-15 fifteen component bladder regeneration composition designed and intended to regenerate failing bladders back to their original health and function. Numerous independent studies have confirmed the ability for electrical stimulation and stem cell injections to improve bladder function. Current Status – We are building and testing prototypes in our lab. We filed patent claims. We are seeking out research collaborators.

> RegenaLung – Over 3 million people die each year from chronic respiratory diseases. Recent studies have shown the strong potential for stem cell therapy to improve lung recovery including reducing chronic inflammation. Our team has developed the first combination bioelectric stimulator + micro infusion pump + RL-15 fifteen component stem cell based lung regeneration composition therapy for lung regeneration. Current Status – Filed patents. Held potential research collaboration meetings with Cedars Sinai UCLA Dr. Barry Stripp, Mayo Clinic and University of Utah researchers. Preparing to launch translational research studies.

> MucosaCell – Small intestinal submucosa (SIS) is a bio-derived extracellular matrix scaffold with remarkable repairing ability for soft tissue. Our team is working to leverage these healing properties for a variety of applications as a scaffold or hydrogel substrate. We are also working to potentially regenerate sub mucosa tissues throughout the body with a combination of bioelectric stimulation and repeat deliveries of the MC-15 fifteen component sub mucosa regeneration composition via a micro infusion pump. Current Status – Recruited Dr. Stuart Williams as Chief Scientific Officer and we plan to soon initiate research at the University of Louisville Cardiovascular Innovations Research Center. In process of filing patents.

2022 Likely to Be In Position for Securing Strategic Partner

> BioLeonhardt Whole Body – This vision is the most ambitious long term research initiative of the Leonhardt team focused on whole body regeneration. The team is planning to first introduce first Bod-Stim a bioelectric body suit formed into yoga pants, pilates wear and athletic under garments to help people optimize their exercise results and recovery. The ambitious far reach end goal of BioLeonhardt Whole Body is the development of a body regeneration chamber that reduces aging by 30 years and extends life by 30 years by scanning the body and directing stem cell repair of organs. We intend for this product to include inflammation management as early cancer detection and cancer tumor eradication with bioelectric energy and other means. Current Status – First of series of patents filed. First conversations with National Science Foundation Regenerative Medicine SBIR Director about funding. Currently building and preparing for first studies the first Bod-Stim full body suits. Developing strategic partnerships with intelligent textile providers and other key component providers.

> The California Stock ExchangeTM – On path with vision to be the first social good impact stock exchange in the USA. Following the belief that “Doing good and treating people and community well is not jus good for good sake it is good business”. Stock exchange that only lists companies that score high on scoring system based on treating people well, having a sense of purpose, an innovation culture and treating community, health and the environment well. Current Status – The California Stock Exchange TM has launched the Cal-30 30 Social Good Impact Index Fund powered by Motif Investing, Cal-Xports, Cal-X MicroLoans in partnership with ZimpleMoney and KIVA, Cal-X Crowdfund Connect, Cal-X Coffee Shops and Cal-X Funders Club. The team has registered the Trademark for The California Stock ExchangeTM and sold to NBC the TV show Crowdfund The American Dream produced by Go Go Luckey Productions and Cohen Entertainment. Held meetings with numerous potential strategic partners including OTC Markets, TSX Toronto Venture Exchange, Startup Exchange and others. Met with FDA SEC Commissioner Gallagher in Washington D.C. Gave over 50 speeches at meetings on The Jobs Act, Crowdfunding and Financial Reform.

> Leonhardt Food & Beverage – Vision is to sell high quality premium Lionheart and Leonhardt branded food and beverage products to raise funds for organ regeneration research by Leonhardt Ventures and Leonhardt’s Launchpads startups. Lionheart Brands Cooperative Marketing is attempting to consolidate into one marketing initiative Leonhardt Vineyards and Lionheart Wines, Lionheart Cider, Lionheart Kombucha, Lionheart and Leonhardt Craft Beers, Lionheart Health Drinks, Lion and Lionheart coffee and other complimentary products. Leonhardt Vineyards has experience in producing and selling over 180,000 bottles of wine to date – producing Zinfandel, Petite Syrah, Chardonnay, Sauvignon Blanc and Cabernet Sauvignon. Current Status – Developed marketing plan for Lionheart Brands and working to secure contracts with all participating producers. Launched Food Trikes and Scooters www.foodtrikesandscooters.com and built and sold prototype units Lucille’s American Cafe’s launched franchising program – https://leonhardtventures.com/lucilles-cafe/ = flagship restaurant in Weston, Florida is averaging over $2 million in annual sales.

> Kindheart Lionheart Media & Publishing – Vision is to create premier “do good, feel good” producer, creator, distributor and publisher of social good impact content. Inspirational books, movies, TV and music that inspires people to be the best they can be. Current Status – Launched Kindheart Lionheart TV Network – over 3 billion views across all curated programs. Launched Kindheart Lionheart Startup Media Support Services to provide video, web site, newsletter, blog, social media, annual report , logo design, marketing and animation services to social good impact startups. Launched a number of original TV programs = California Love, Love Dialogues, Love Roller Coaster, Covers of Great Speeches, Dolphin Smiles: The Legend of Kindheart Lionheart. Co-produced original short social good impact film = Melody.

> EarCell – Vision is to restore lost hearing with a combination of bioelectric stimulation and stem cell + growth factor infusions. Current Status – Recently upgraded web site www.ear-cell.com Seeking potential research collaborators. Recruited Ken Evans as President. Teamed with Fluid Synchrony LLC in Pasadena, CA for micro pump development.

> HeartScore – Vision is to integrate high level monitoring including bioelectric and other means of scanning and bioelectric treatment into comprehensive heart failure, inflammation and stroke management programs. HearScore also intends to publish an annual ranking list for top innovations of the year related to cardiovascular medical technologies. Current Status – Filed numerous patents. Developed comprehensive program for heart, inflammation and stroke management. Preparing for studies. Compiling HeartScore 2017 Top Cardiovascular Innovations of the Year publication list.

WARNING: Any forward looking product performance claims are the personal opinion of startup founders modified by “designed or intended to”. All research is early stage and and data at this time is not statistically significant to be able to make any product performance claims. By nature of being brief elevator pitches fail to properly list out all associated risks and obstacles.

Cal-X Stars Business Accelerator, Inc. royalty agreements for patent licenses.

3% royalty on sales of MilkStim bioelectric milk stimulation products.
Note – Early data from MilkStim bioelectric milk production stimulation studies in cows in Argentina show substantial increases in milk yields.

3% royalty on sales of StimVet veterinary products accelerator products.

Here is a link to our Leonhardt Ventures 2017 Annual Report which is our best introduction document


Leonhardt’s Launchpads is the innovation and startup accelerator arm of Leonhardt Ventures founded by Howard J. Leonhardt in 1982. Howard Leonhardt is an inventor and serial entrepreneur with 21 issued organ regeneration and recovery patents and dozens of more patent claims pending at the USPTO – https://patents.justia.com/inventor/howard-j-leonhardt. Leonhardt Ventures has been bringing organ regeneration and recovery innovations to market since 1982. In the 1980’s they patented and pioneered cardiovascular balloon catheter development – PolyCath. In the 1990’s they patented and developed the leading stent graft system for endovascular repair of aortic aneurysms TALENT and the first percutaneous heart valve. Their team completed the first ever stem cell repair of an animal heart in 1988 and landmark first-ever non-surgical stem cell repair of a human heart in 2001. In 1999 they published their first paper on bioelectric based organ regeneration in CIRCULATION. Leonhardt Ventures has raised over $140 million to fund its startups since its founding and has had primary exits valued at $440 million and secondary exits exceeding $4.3 billion. In 2008 they opened up their first incubator/accelerator in Northern California followed in 2013 in Southern California and 2015 in Utah. These accelerators currently incubate 30 startups 27 of which are focused on bioelectric and endovascular based organ regeneration and recovery. Most of the startups in the accelerator are based on Leonhardt’s patented and patent pending bioelectric stimulation platform technology for stem homing, proliferation and differentiation and organ regeneration via controlled protein expressions. The 2017 startup portfolio is the culmination of over 35 years experience in organ regeneration and recovery research and experimentation.

Our accelerator business model is to advance each startup to first-in-man results and then sell to a strategic partner/buyer preferably with a 3% royalty forward on net sales. Our goal is 23X ROI on accelerator shares and 63X on individual startup shares after 5 years. See schedule chart below of expected exits timing over the next 5 years.

Investments at this time are all 2:1 meaning if you invest $30,000 in the innovation accelerator you receive $30,000 worth of shares of the accelerator stock AND also a 2:1 a warrant valued at $30,000 to acquire at no further charge $30,000 worth of shares of any or all of the 30 startups in the 2017 accelerator portfolio class–  You have until Dec. 31st of the year you invest to decide your allocation of your warrant to any or all of the startups you choose.

The startups generally are owned as follows = 50.1% owned by Leonhardt Ventures LLC, 9 to 20% owned by Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads and the balance 29.9% to 40.9% owned by management, advisors and outside shareholders. The startups generally start out with a valuation of $2.3 to $5 million and the target goal is to sell them in 5 years or after first-in-man data comes in, which ever comes first, at $240 to $800 million with ideally a 3% royalty on net sales forward. We strive as a goal to keep dilution to 37% over 5 years with our anti-dilutive business model.

Slide Deck from Annual Shareholder Meeting May 2017 > Click Here

Here are the current valuations and shares prices for each startup in our accelerators in California and Utah – https://leonhardtventures.com/our-companies/#toggle-id-2

Product Groups:

1. Heart & Cardiovascular.
2. Brain.
3. Cosmetic & Personal Care.
4. Major Organ Regeneration.
5. Cancer.
6. Regenerative Economy.

Our fall 2016 Newsletter has convenient links to all our videos for each startup in once place > – Click Here

Here is a link to photos and bios of our team members >Click Here

Our Scientific Advisory Board > Click Here

Attached are updated Executive Summaries for Cal-X Stars Business Accelerator, Inc. DBA Leonhardt’s Launchpads.

Top 6 startups in our accelerator ripe for finding a strategic buyer in 2018…

1. OrthodontiCell > completing animal studies now at Forsyth Institute moving to clinical studies at Tufts and UCSF.
2. VascuStim > completed pilot clinical studies with success now moving to large registry clinical trial.
3. Second Heart Assist, Inc. > completed Phase I large animal studies moving to Phase II in November and hope to be in clinical studies early next year.
4. Stem Cell Bra > completed Phase I sheep studies with success now moving to Phase II studies.
5. HairCell > launching clinical trials in Canada, Argentina and Mexico.
6. BioLeonhardt > completing two animal studies in Utah.

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2019..

1. CancerCell > launching lab and animal studies with Pacific NeuroSciences Center in Los Angeles and Harbor UCLA.
2. CerebraCell > launching lab and animal studies with Pacific NeuroSciences Center in Los Angeles and Harbor UCLA.
3. MyoStim ED > just applied for NIH grant with UCLA.
4. SkinCell Stimulator by MyoStim Skin > preparing to launch clinical studies OUS.
5. PancreaCell > preparing for grant applications with U of Miami Diabetes Research Institute.
6. PressureStim > just filed patent application.

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2020…

1. Valvublator > preparing to build test prototypes with Biomerics.
2. LiverCell > preparing for animal studies at Duke University.
3. BioPace > filed NIH grant application with U of Utah. Preparing new applications.
4. AortaCell > filed patent application.
5. DentaCell > preparing numerous studies. Meeting next Thursday with investigator Los Angeles .
6. EyeCell > completing animal studies at U of Utah with partial grant support.

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2021

1. InStim > filed patent application.
2. CoroStim VibroCell > filed patent application. Building prototypes.
3. KidneyCell > filed patent application.
4. BladderCell > seeking out research partners.
5. RegenaLung ECMOCath and COPD > seeking out research partners.
6. MucosaCell > launching research at U of Louisville.

Top 6 startups in our accelerator ripe for finding a strategic partner/buyer in 2022

1. BioLeonhardt Whole Body > applying for NSF SBIR grant application.
2. The California Stock ExchangeTM > met with TSX Toronto Venture Exchange about partnership working to close.
3. Leonhardt Food & Beverage > preparing cooperative marketing launch.
4. Kindheart Lionheart Media & Publishing > preparing ad sales launch.
5. EarCell > filed patent application. Seeking research partners.
6. HeartScore > filed patent application. Seeking research partners.

OUR TEAM profiles > https://leonhardtventures.com/team/

Our Scientific Advisory Board > https://calxstars.com/scientific-advisory-board/

Here are profiles of Dr. Mark Kroll, Dr. Navin Kapur, Dr. James W. Kronberg, Dr. John Langell and Dr. Ron Waksman the latest additions to our team…

The Idea Man | Minnesota Business Magazine
With over 300 patents, mark Kroll leads the market on medical device design. … As one of the most prolific inventors of medical devices in the world, Dr. Mark Kroll, retired chief technology officer and senior vice president from St. Jude Medical, knows what it means to improve …

Navin Kapur | Professional Profile – LinkedIn
View Navin Kapur’s profile on LinkedIn, the world’s largest professional community. Navin’s experience … Summary. Dr. Kapur is an Associate Professor in the Department of Medicine. … Director, CardiacBiology Research Center (CBRC).

James W. Kronberg Inventions, Patents and Patent … – Justia Patents
James W. Kronberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have …

John Langell, MD, PhD, MPH, MBA, FACS | Professional Profile
Salt Lake City, Utah – ‎–UNIVERSITY LEADERSHIP AND HEALTHCARE EXECUTIVE | Large Institutional Leadership | Innovation | Quality Improvement – ‎Xenocor
John Langell, MD, PhD, MPH, MBA, FACS … View John’s Full Profile … of the University of Utah School of Medicine in Salt Lake City, where I drive almost two dozen …. Center for Medical Innovation | University of Utah Health Sciences Center, …

Ron Waksman – MedStar Health Research Institute
Jan 23, 2015 – Ron Waksman, MD, FACC, is Associate Director, Division of Cardiology … Dr. Waksman has authored/co-authored 310 published manuscripts and … of the annual Cardiovascular Revascularization Therapies (CRT) meeting, …

Here are some big milestones coming up…

> Second Heart presentation at TCT Denver last week of October 2017
> Second Heart Phase II large animal study at Tufts Medical Center Boston completed first week of November.
> Second Heart FDA filing pre-submission for Early Feasibility Study. Set to meet FDA Jan. 16th in D.C.
> New Caltech patent license for circulatory assist support.
> Second Heart presentation DHF Berlin December 15th an 16th Berlin, Germany – http://www.csi-congress.org/dhf.php?go=700
> BioLeonhardt heart regeneration completing small and large animal studies at U of Utah with grant support $300,000.
> BioLeonhardt heart regeneration filing grant application with Texas Heart Institute Dr. Doris Taylor.
> VascuStim diabetic foot ulcer treatment launching clinical registry study worldwide bioelectric + amniotic fluid membranes.
> Valvublator heart valve decalcification and regeneration – building out first test prototypes.
> VibroCell vibrational energy device for preventing blood clots. Patent app is filed. Building out test prototypes soon.

> Launching translational studies at Pacific Neurosciences Institute and LABiomed Harbor UCLA Los Angeles.
> Filing new patent application for concussion.

> Phase II large animal studies for Stem Cell Bra breast tissue generation in Argentina.
> OrthdontiCell moving into definitive animal studies at Forsyth Institute Boston.
> OrthdodontiCell preparing for first-in-man studies at Tufts University, UCLA, and UCSF San Francisco.
> HairCell heart regeneration clinical studies launch in Argentina and Canada.
> DentaCell bioelectric and stem cell dental products innovation accelerator launch.
> SkinCell Stimulator by MyoStim Skin is preparing for OUS first-in-man studies.

> Completing EyeCell eye regeneration studies at U of Utah with partial grant support.
> Filing bioelectric inflammation control patents.
> Completing new round of sheep studies for Stem Cell Bra breast tissue generation.
> DentaCell Accelerator screening hundreds of innovations to join 2018 portfolio.
> SkinCell Stimulator by MyoStim Skin completing safety studies with intent to launch clinical studies OUS in 2018 for skin regeneration.
> MyoStim ED applied for NIH grant for bioelectric treatment of erectile dysfunction with UCLA researchers @ LA BioMed.
> HairCell is preparing for clinical studies in Canada and other locations in 2018.

> CancerCell is launching translational studies at Pacific NeuroSciences Institute and John Wayne Cancer Institute Santa Monica, CA.
> Filing new bioelectric cancer patents for CancerCell to add to already large estate in area.

> The California Stock ExchangeTM is working to close agreement with potential strategic partners.
> Hiring ad Sales Manager for Kindheart Lionheart TV Network.
> Launching Lionheart Brands Cooperative Marketing.


QUOTE – “These are forward looking projections. As we are a startup the only thing we can guarantee is that we will miss them over and over again, until we survive our own mistakes” Rachid Sefrioui, Professional Investor, Venture Capitalist @ Finaventures, Entrepreneur

By nature of being extremely short in scope elevator pitches leave out relevant risks and can be misleading in portraying a technology or company to be better than it may appear if a more lengthy and comprehensive presentation is made. The conciseness of the language by nature is slanted to the positive and de-emphasizes risks and obstacles.

These risks include…
1. Startups may not have or secure resources to brings it products to market.

2. None of these startups have tested their products sufficiently enough to make any definitive product or company performance claims.

3. The startups patents pending may not be issued. Patent license agreements may not hold up.

4. All the company agreements, including patent licenses, supply and research agreements are subject to conditions which may not be met or may not have already been met to keep them active and enforceable.

5. The company with a small staff undertaking so many activities is bound to have mistakes in information and outdated information on selected web sites and other documents.

6. Any early stage investment is high risk but these startups are even higher risk since they attempt to take on very large medical problems where other firms with much more substantial resources have failed.

7. No other firm has been highly successful financially in stem cell or bioelectric based organ regeneration. Most of the startups in these accelerators are attempting to do something which has never been done before.

8. Traditionally it costs hundreds of millions of dollars just to bring one of these products to market and many years of development by a focused team of professionals. This accelerator business model attempts to bring up to 30 innovations through first-in-man studies with a substantially smaller staff with dramatically substantially less resources than our traditionally required for even one startup of this type. This in and of itself is and indicator of associated extremely high investment risk.

9. Personnel highlighted as being involved in the projects and startups are nearly all part time and are not compensated most often by cash. Many consultants and advisors listed limit their help to a few hours annually. A number do not have signed agreements in place and are working with the companies in a less formal capacity.

10. Research projects started may not be finished for a variety of reasons.

These elevator pitches do not purport to be all-inclusive or necessarily to contain all the information that a prospective investor may desire in investigating the Company, and may be subject to updating, withdrawal, revision or amendment. No representation or warranty, express or implied, is or will be given by Leonhardt’s Launchpads, the Company, their advisers or any of their respective directors, shareholders, partners or employees as to the accuracy or completeness of the pitches or the information or opinions contained therein.
Any financial projections given are illustrative only and none of the projections or assumptions should be taken as promises on the part of the Company nor should they be taken as implying any indication, assurance or guarantee that those assumptions are correct or exhaustive.

These pitches contain forward-looking statements. These statements relate to, amongst other things, the Company’s future prospects, developments and business strategies. Forward-looking statements are identified by their use of terms and phrases such as “believe”, “could”, “envisage”, “estimate”, “intend”, “may”, “plan”, “will” or the negative of those, variations or comparable expressions, including references to assumptions.

The forward-looking statements in this Pitch are based on current expectations and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by those statements. If one or more of these risks or uncertainties materialises, or if underlying assumptions prove incorrect, the Company’s actual results may vary materially from those expected, estimated or projected. Given these risks and uncertainties, potential investors should not place any reliance on forward looking statements. These forward-looking statements are made only as at the date of the Pitch.

Each recipient of these Pitches must make their own independent assessment of the information provided by the Company and is recommended to seek independent advice on the contents hereof from an authorized person specializing in advising on investments of the kind in question. Neither the Company, Leonhardt’s Launchpads, nor any of their advisers, nor their respective directors, partners, representatives, agents, consultants or employees shall be liable for any direct, indirect or consequential loss or damage suffered by any person relying on statements or omissions from the Pitch and to the maximum extent permitted by law, all conditions, warranties and other terms which might be implied by statute, common law or the law of equity and any such liability are expressly excluded. The Pitch should not be construed as a recommendation to prospective investors by the Company or Leonhardt’s Launchpads, Cal-X Stars Business Accelerator, Inc., or any of their respective officers to invest in the Company, and does not form any commitment by the Company to proceed with an investment. The Company and Leonhardt’s Launchpads, Leonhardt Ventures or Cal-X Stars Business Accelerator, Inc. reserve the right to terminate the procedure at any time and to terminate any discussions and negotiations with any prospective investors at any time and without giving any reason.

Any and all discussions, negotiations and communications, including through any online forums, between any recipient of the Pitches and the Company and their respective directors, shareholders, employees, advisers and/or representatives will remain subject to contract. Any person who invests in the Company at any time must comply with all applicable laws and regulations in force in any jurisdiction in which they acquire, offer or sell shares and must obtain any consent, approval or permission required in respect of any such transaction under the laws and regulations in force in any jurisdiction to which they are subject or in which any such transaction takes place or in which they possess the Pitch. Neither the Company, Leonhardt’s Launchpads, nor any of their respective directors, partners, representatives, agents, consultants or employees shall have any responsibility for any such matters.

The distribution of the Pitches in certain jurisdictions other than California may be restricted by law and therefore persons accessing the Pitch into whose possession the Pitch documents come should inform themselves about and observe any such restrictions. Any failure to comply with these restrictions may constitute a violation of securities laws of any such jurisdiction. Recipients represent and warrant to the Company and Leonhardt’s Launchpads, that they are able to receive the Pitches without contravention of applicable legal or regulatory restrictions in the jurisdiction in which they reside, conduct business or receive the Pitches, including in particular the requirements of the Act.

The individual startups accept highlighted in this listing of elevator pitches accept responsibility for the information contained in each Pitch. The Pitches are meant to only reflect the most positive and optimistic personal opinion of the company founders and nothing more or less. To the best of the knowledge and belief of the Company (who has taken all reasonable care to ensure that such is the case) the information contained in this Pitch is in accordance with the facts and there are by the extreme brief nature of the few line elevator pitches there are indeed facts the omission of which would affect the validity of such information. This information may be obtained elsewhere such as our private placement memorandum, our annual report or the risk and warnings disclaimers proceeding and following the elevator pitches on this page or on the individual startup web sites. These risks include in brief – patents cited may not protect us, patent license agreements may not hold up, patents pending may not be issued, company lacks resources to complete research, early data is not enough to determine definitively if technology works, all agreements are subject to conditions being met and due to lack of financial resources the likelihood and risk of not meeting such conditions is high, many agreements may not be properly ratified or signed, company is underfunded and understaffed and personnel aboard have diverted attention with other jobs and many projects.

The information contained in the Updates section and the Q&A section and any downloaded documents do not form part of the Pitch and have not been reviewed or approved by Leonhardt’s Launchpads Board of Directors or Legal Counsel. Similarly, any information published outside of the Leonhardt’s Launchpads web sites, including on social media platforms (e.g. Facebook, Twitter) or the Company’s news blog, does not form part of the Pitches. Leonhardt’s Launchpads, Leonhardt Ventures and Cal-X Stars Business Accelerator, Inc. assumes no responsibility for information contained in the Q&A or Updates section, downloads or in any form of media outside the Leonhardt’s Launchpads accelerator and such information should not be deemed an offer or invitation to invest or be relied on to invest.

Potential investors should be aware of the risks associated with an investment in the Company especially at an early stage in its development and should ensure that they have read and understood the Risk Warning on the Leonhardt’s Launchpads, Cal-X Stars Business Accelerator, or Leonhardt’s Launchpads websites before continuing. If any potential investors are in any doubt regarding the contents of any Pitches, they must consult their own professional financial advisers.

Investment in the Company carries substantial risk and may involve special risks that could lead to a loss of all or a substantial amount of such investment. Unless prospective applicants for shares fully understand and accept the nature of the Company and the potential risks inherent in the Company they should not invest in the Company. A prospective investor should consider carefully whether an investment in the Company is suitable for themselves in the light of their personal circumstances, the economic climate and the financial resources available to them. There can be no assurance that the Company’s objectives in respect to any of its funds will be achieved and investment results may vary substantially over time. As such, an investor’s capital may be at risk.